Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Streptokinase. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Streptokinase. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Streptokinase. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Streptokinase is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Streptokinase. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Streptokinase. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Obinutuzumab. |
| Rivaroxaban | Streptokinase may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Streptokinase. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Streptokinase. |
| Urokinase | Urokinase may increase the anticoagulant activities of Streptokinase. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Streptokinase. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Streptokinase. |
| Aprotinin | The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin. |
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Streptokinase is combined with Duloxetine. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Streptokinase is combined with Levodopa. |
| Risperidone | Streptokinase may increase the hypotensive activities of Risperidone. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Streptokinase. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Streptokinase. |
| Quinine | The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Streptokinase. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Streptokinase. |
| Ardeparin | Streptokinase may increase the anticoagulant activities of Ardeparin. |
| Heparin | Streptokinase may increase the anticoagulant activities of Heparin. |
| Enoxaparin | Streptokinase may increase the anticoagulant activities of Enoxaparin. |
| Sulodexide | Streptokinase may increase the anticoagulant activities of Sulodexide. |
| Semuloparin | Streptokinase may increase the anticoagulant activities of Semuloparin. |
| Danaparoid | Streptokinase may increase the anticoagulant activities of Danaparoid. |
| Dalteparin | Streptokinase may increase the anticoagulant activities of Dalteparin. |
| Tinzaparin | Streptokinase may increase the anticoagulant activities of Tinzaparin. |
| Nadroparin | Streptokinase may increase the anticoagulant activities of Nadroparin. |
| Bemiparin | Streptokinase may increase the anticoagulant activities of Bemiparin. |
| Parnaparin | Streptokinase may increase the anticoagulant activities of Parnaparin. |
| Reviparin | Streptokinase may increase the anticoagulant activities of Reviparin. |
| Pentoxifylline | The therapeutic efficacy of Streptokinase can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Streptokinase. |
| Levocarnitine | The therapeutic efficacy of Streptokinase can be increased when used in combination with Levocarnitine. |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Streptokinase. |
| Aripiprazole lauroxil | Aripiprazole lauroxil may increase the hypotensive activities of Streptokinase. |
| Nicorandil | Nicorandil may increase the hypotensive activities of Streptokinase. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Streptokinase. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Streptokinase. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Streptokinase. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Streptokinase. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Streptokinase. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Streptokinase. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Streptokinase. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Streptokinase. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Streptokinase. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Streptokinase. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Streptokinase. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Streptokinase. |
| Equol | Equol may decrease the anticoagulant activities of Streptokinase. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Streptokinase. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Streptokinase. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Streptokinase. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Streptokinase. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Streptokinase. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Streptokinase. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Streptokinase. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Streptokinase. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Streptokinase. |
| Estriol | Estriol may decrease the anticoagulant activities of Streptokinase. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Streptokinase. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Streptokinase. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Streptokinase. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Streptokinase. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Streptokinase. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Streptokinase. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Streptokinase. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Streptokinase. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Streptokinase. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Streptokinase. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Streptokinase. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Streptokinase. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Streptokinase. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Streptokinase. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Streptokinase. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Streptokinase. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Streptokinase. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Streptokinase. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Streptokinase. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Streptokinase. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Streptokinase. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Streptokinase. |